LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・Edwards Lifesciences Corp

Edwards Lifesciences Corp

Затворен

Сектор Здравеопазване

66.76 1.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

65.69

Максимум

67.02

Ключови измерители
By Trading Economics
Приходи	14M 366M
Продажби	30M 1.6B
P/E Средно за сектора	39.81 103.001
EPS	0.7
Марж на печалбата	22.472
Служители	19,800
EBITDA	-59M 417M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+22.08 upside

Дивиденти
By Dow Jones
Следващи печалби	23.10.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-289M 42B
Предишно отваряне	65.5
Предишно затваряне	66.76

Настроения в новините

By Acuity

56%

44%

287 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

64.7 / 68.66 Подкрепа & съпротива

Edwards Lifesciences Corp Графика

Свързани новини

15.07.2024 г., 13:57 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences to Buy Innovalve for $300 Million

3.09.2024 г., 20:38 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences: After Recent Accelerated Repurchase Agreement and August Buybacks Via 10b5-1 Agreement and Open Market Repurchases, Company Has $1.4B in Remaining Authorization

3.09.2024 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Completes Sale of Critical Care Group to Becton Dickinson for $4.2B

3.09.2024 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Authorizes $1.5B of Additional Share Repurchases

25.07.2024 г., 09:02 ч. UTC

Печалби

Горещи акции

Stocks to Watch Thursday: Ford, IBM, Chipotle, American Airlines -- WSJ

25.07.2024 г., 08:40 ч. UTC

Топ новини

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

24.07.2024 г., 20:17 ч. UTC

Печалби

Edwards Lifesciences: Expects 2024 Edwards Sales Growth of 8% to 10% >EW

24.07.2024 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

24.07.2024 г., 20:15 ч. UTC

Печалби

Edwards Lifesciences 2Q Sales $1.39B >EW

24.07.2024 г., 20:15 ч. UTC

Печалби

Edwards Lifesciences 2Q Net $366.3M >EW

24.07.2024 г., 20:15 ч. UTC

Печалби

Edwards Lifesciences 2Q Adj EPS 70c >EW

24.07.2024 г., 20:15 ч. UTC

Печалби

Edwards Lifesciences 2Q EPS 61c >EW

15.07.2024 г., 13:42 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences to Buy Innovalve for $300M

15.07.2024 г., 13:01 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences: SAPIEN M3 Remains on Track to Become First Approved Transfemoral TMVR System in Europe by End of 2025 >EW

15.07.2024 г., 13:01 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences: Acquisition Enhances TMVR Technologies to Address Large Unmet Structural Heart Patient Needs >EW

15.07.2024 г., 13:00 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences to Acquire Innovalve Bio Medical Ltd., Early-Stage Transcatheter Mitral Valve Replacement Co >EW

15.07.2024 г., 13:00 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences To Acquire Innovalve >EW

4.06.2024 г., 17:26 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3.06.2024 г., 13:26 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3.06.2024 г., 12:25 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

3.06.2024 г., 11:03 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2B in Cash

3.06.2024 г., 10:40 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences To Sell Its Critical Care Product Group For $4.2 Billion To Becton Dickinson -- MarketWatch

3.06.2024 г., 10:32 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson: Acquired Business Has About 4,500 Employees >BDX EW

3.06.2024 г., 10:31 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson: Acquired Business Generated More Than $900 Million Revenue in 2023 >BDX

3.06.2024 г., 10:31 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson: Deal Expands Portfolio of Smart Connected Care Solutions >BDX EW

3.06.2024 г., 10:30 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson to Buy Edwards Lifesciences Critical Care Product Group for $4.2 Billion >BDX EW

3.06.2024 г., 10:30 ч. UTC

Придобивния, сливания и поглъщания

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Billion To Expand Smart Connected Care Solutions And Become An Advanced Monitoring Technology Leader >BDX EW

26.04.2024 г., 20:10 ч. UTC

Печалби

This 'Critical' Business Helped Edwards Lifesciences Offset Its TAVR Miss -- IBD

25.04.2024 г., 21:05 ч. UTC

Печалби

Edwards Lifesciences Nabs Quarterly Beat And Plans A 'Critical' Spinoff -- IBD

25.04.2024 г., 20:32 ч. UTC

Печалби

Edwards Lifesciences Nabs Quarterly Beat And Plans A 'Critical' Spinoff -- IBD

Сравнение с други в отрасъла

Ценова промяна

Edwards Lifesciences Corp Прогноза

Ценова цел

By TipRanks

22.08% нагоре

12-месечна прогноза

Среден 80.6 USD 22.08%

Висок 91 USD

Нисък 70 USD

Според 23 анализатори от Wall Street, предложили 12-месечна ценова цел за Edwards Lifesciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

23 ratings

Купи

Задържане

Продай

Според 23 анализатори, дали борсови рейтинги на Edwards Lifesciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

64.7 / 68.66Подкрепа & съпротива

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Настроение

By Acuity

287 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease. Its Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.